Abeome issues DiSH™ licenses for use to commercial users. The license includes Abeome’s patented Sp2ab myeloma fusion partner, a genetically modified cell line which results in hybridomas that both secrete antigen-specific antibody and express antibody on the cell surface. Surface-bound antibodies allow antigen-specific hybridomas to be labeled and efficiently sorted by fluorescence-activated cell sorting (FACS) or magnetic separation.
Culture, fusion, selection and recovery media for creation and isolation of may be purchased separately. A User’s Guide and ongoing support are also provided.
Research and Universities
Abeome works closely with researchers in the private sector and at Universities who wish to substantially improve their discovery cycle times.